论文部分内容阅读
目的探讨肾康注射液联合替米沙坦和盐酸贝那普利治疗糖尿病肾病的临床疗效。方法选取2014年1月—2015年10月上海市浦东新区人民医院肾脏内科收治的糖尿病肾病患者94例,随机分为对照组和治疗组,每组各47例。对照组口服盐酸贝那普利片,10 mg/次,1次/d;同时口服替米沙坦片,40 mg/次,1次/d。治疗组在对照组治疗基础上静脉滴注肾康注射液,100 m L加入250 m L生理盐水,1次/d。两组患者均连续治疗4周。观察两组的临床疗效,比较两组治疗前后血肌酐(Scr)、血尿素氮(BUN)、24 h尿蛋白(24 h Upro)、收缩压(SBP)、舒张压(DBP)、尿白蛋白排泄率(UAER)、内生肌酐清除率(Ccr)、QLQ-C评分、KPS评分和HAD评分的变化情况。结果治疗后,对照组和治疗组的总有效率分别为78.72%、93.62%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者Scr、BUN、24 h Upro、SBP、DBP、UAER、HAD评分均较同组治疗前明显降低,Ccr、QLQ-C评分、KPS评分较治疗前升高,同组治疗前后差异有统计学意义(P<0.05);治疗后治疗组Scr、BUN、24 h Upro、UAER、Ccr、HAD评分、QLQ-C评分、KPS评分的改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。结论肾康注射液联合替米沙坦和盐酸贝那普利治疗糖尿病肾病具有较好的临床疗效,可有效改善患者的肾功能,提高患者的生活质量和活动状态,有利于患者负面情绪的缓解,具有一定的临床推广应用价值。
Objective To investigate the clinical effects of Shenkang injection combined with telmisartan and benazepril hydrochloride in the treatment of diabetic nephropathy. Methods From January 2014 to October 2015, 94 patients with diabetic nephropathy admitted to Department of Nephrology, Pudong New Area People’s Hospital of Shanghai were randomly divided into control group and treatment group, 47 cases in each group. The control group benazepril hydrochloride tablets, 10 mg / time, 1 / d; oral telmisartan tablets, 40 mg / time, 1 / d. Treatment group in the control group based on the treatment of intravenous infusion of renal Kang injection, 100 m L added 250 m L normal saline, 1 / d. Two groups of patients were treated for 4 weeks. The clinical curative effect of the two groups was observed. The levels of Scr, BUN, 24 h Upro, SBP, DBP, urinary albumin UAER, Ccr, QLQ-C score, KPS score and HAD score. Results After treatment, the total effective rate of the control group and the treatment group were 78.72% and 93.62%, respectively, with significant difference between the two groups (P <0.05). After treatment, Scr, BUN, 24 h Upro, SBP, DBP, UAER and HAD scores of both groups were significantly lower than those before treatment, Ccr, QLQ-C score and KPS score were higher than those before treatment (P <0.05). After treatment, the improvement rates of Scr, BUN, 24 h Upro, UAER, Ccr, HAD score, QLQ-C score and KPS score in the treatment group were better than those in the control group Statistical significance (P <0.05). Conclusion Shenkang injection combined with telmisartan and benazepril hydrochloride in the treatment of diabetic nephropathy has a good clinical efficacy, which can effectively improve the patient’s renal function, improve patient quality of life and activity, help patients with negative emotions , With a certain clinical application value.